|
|---|
|
|
|
|
|
y*****l
发帖数: 5997 | 1 系统测试盈利率很高，可是扫出来的图形不太好看。只考虑RSI，没有考虑基本面。还
需要时间来检验，有兴趣的可以看看。另外，今天扫出来的大多数是卖出信号，提醒大
家减仓。YMYD
http://finviz.com/screener.ashx?v=341&t=VICL,LACO,CXDC,ARNA,CVO | y*****l
发帖数: 5997 | 2 This is a bottom system. The backtest showing over
90% profitable in 3 months and about 80% in 6 months. It needs add stop lost
for downtrend stocks. This systems along with other systems, such as
breakup, 3+1, are all under testing. YMYD
BTW, I only bot CVO among these picks.
Insider buys:
August 20, 2010 Green, Leonard C
Directors Purchase -- $13.2K 2,000.00 $6.59 - 6.59 824,507.00
August 19, 2010 Green, Leonard C
Directors Purchase -- $6.6K 1,000.00 $6.56 - 6.56 822,507.00
August 13, 2010 Burton, Robert G Sr
Officers Purchase -- $249.7K 45,000.00 $5.55 - 5.55 2,687,170.00 | f**********g
发帖数: 2252 | 3 LACO, CXDC, ARNA,CVO all up.
【在 y*****l 的大作中提到】
: 系统测试盈利率很高，可是扫出来的图形不太好看。只考虑RSI，没有考虑基本面。还
: 需要时间来检验，有兴趣的可以看看。另外，今天扫出来的大多数是卖出信号，提醒大
: 家减仓。YMYD
: http://finviz.com/screener.ashx?v=341&t=VICL,LACO,CXDC,ARNA,CVO
| f**********g
发帖数: 2252 | 4 Kevin's father, could u say sth about VICL? Very pig.
Vical to manufacture plasmid DNA vaccines against HIV
Monday 10/11/2010 9:42 AM ET - Datamonitor
Related Companies
Symbol Last %Chg
VICL 2.23 -1.33%
As of 10:29 AM ET 10/11/10
Vical, a biopharmaceutical company, has agreed to manufacture plasmid DNA
vaccines against HIV under a $2.4 million contract with the IPPOX Foundation
, a collaborating institution for the Poxvirus Vaccine Regimen Design led by
the Centre Hospitalier Universitaire Vaudois under the auspices of the
collaboration for AIDS vaccine discovery.
The current project is investigating whether the second generation DNA/
poxvirus vaccine approach combined with immunization strategies can induce
increased and balanced Env, Gag, Pol and Nef HIV-1-specific T-cell responses
in humans.
Vical will produce individual plasmids encoding selected portions of the Env
and Gag antigens, and one plasmid encoding selected portions of the Pol and
Nef antigens. These plasmids will be combined and delivered as a single
vaccine. Delivery is expected to be completed in the fourth quarter of 2010.
Vical signs agreement with IPPOX Foundation for Plasmid DNA (pDNA) vaccines
Thursday 10/07/2010 3:03 PM ET - Datamonitor Financial Deals Tracker
Related Companies
Symbol Last %Chg
VICL 2.23 -1.33%
As of 10:30 AM ET 10/11/10
Vical, Inc., a biopharmaceutical company, has signed an agreement with IPPOX
Foundation for the manufacturing of plasmid DNA (pDNA) vaccines against HIV
. The contract is valued at $2.4 million.
IPPOX Foundation is a collaborating institution for the Poxvirus Vaccine
Regimen Design (PVRD). Both the partners are based in the US.
Under the agreement, Vical will produce individual plasmids encoding
selected portions of the Env and Gag antigens, and one plasmid encoding
selected portions of the Pol and Nef antigens. These plasmids will be
combined and delivered as a single vaccine. Delivery is expected to be
completed in the fourth quarter of 2010.
Deal Value (US$ Million) 2.4
Deal Type Partnership
Sub-Category Manufacturing
Deal Status Announced: 2010-10-07
Deal Participants
Partner 1 (Company) IPPOX Foundation
Partner 2 (Company) Vical, Inc. |
|
|
|
|
|
|
